Evidence map›Paper›PMID 40709615›Full record

ArticleCancer medicine2025

Anti-Angiogenic Agents for Advanced Hepatocellular Carcinoma Induce Liver Atrophy.

Taijiro Wake, Tomoharu Yamada, Ryosuke Tateishi, Makoto Moriyama, Yuki Matsushita, Kazuya Okushin, Takuma Nakatsuka, Masaya Sato, Tatsuya Minami, Yotaro Kudo and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Taijiro WakeDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tomoharu YamadaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ryosuke TateishiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3021-2517
Makoto MoriyamaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yuki MatsushitaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kazuya OkushinDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Takuma NakatsukaDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masaya SatoDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Tatsuya MinamiDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yotaro KudoDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitsuhiro FujishiroDepartment of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Funding

Health, Labour, and Welfare Policy Research Grants from the Ministry of Health, Labour, and Welfare of JapanJapan Agency for Medical Research and Development (AMED) JP25fk0210149JSPS KAKENHI 24K11064JSPS KAKENHI 24K11106
6 · The paper itself

Abstract

aimSystemic therapy for advanced hepatocellular carcinoma (HCC) includes multi-kinase inhibitors with anti-vascular endothelial growth factor (VEGF) activity and anti-VEGF monoclonal antibodies in combination with immune checkpoint inhibitors. This study aimed to investigate and compare the chronological changes in liver volume between patients who received atezolizumab plus bevacizumab (Atezo/Bev) and those who received lenvatinib.

methodsWe enrolled patients who received initial treatment with either Atezo/Bev or lenvatinib for advanced HCC between October 2018 and May 2023. Patients underwent periodic computed tomography (CT) or magnetic resonance imaging (MRI) to evaluate systemic therapy effects. Patients with portal vein thrombosis or prior liver resection/transplantation were excluded. Liver volume was measured at baseline and at 8 and 16 weeks after the initiation of treatment using commercially available software. Liver volume at each time point was expressed as a proportion relative to baseline. A linear regression analysis was used to analyze the chronological changes in liver volume.

resultsSeventy-three patients (40 in the Atezo/Bev group and 33 in the lenvatinib group) were included in this retrospective study. Liver volume decreased in 54 patients (74%) at week 8; the average volume relative to baseline was 0.92 (95% confidence interval: 0.90-0.94, p < 0.01). Liver volume decreased in patients with both shrinking and enlarged tumors. Multivariate analysis indicates that the decrease in nontumoral liver volume was more significant in the lenvatinib group than in the Atezo/Bev group (p = 0.04).

conclusionsAnti-angiogenic therapy for advanced HCC can lead to liver atrophy.

Indexed as

Angiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiverLiver NeoplasmsAgedAntibodies, Monoclonal, HumanizedAtrophyBevacizumabFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPhenylurea CompoundsQuinolinesAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedatezolizumabBevacizumablenvatinibPhenylurea CompoundsQuinolinesanti‐programmed cell death ligand 1atezolizumabbevacizumabChild‐Pugh scorecomputed tomographyimmune checkpoint inhibitorlenvatinibliver volumemagnetic resonance imagingvascular endothelial growth factor

Identifiers

PMID40709615
PMCPMC12290651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.